Evidence map›Paper›PMID 33528734›Full record

ReviewActa diabetologica2021

Novel biomarkers of diabetic kidney disease: current status and potential clinical application.

Federica Barutta, Stefania Bellini, Silvia Canepa, Marilena Durazzo, Gabriella Gruden

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Acta diabetologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Implication of serum soluble IL-2 receptor α in type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Federica BaruttaDepartment of Medical Sciences, University of Turin, Turin, Italy. federica.barutta@unito.it.ORCID http://orcid.org/0000-0001-9319-5123
Stefania BelliniDepartment of Medical Sciences, University of Turin, Turin, Italy.
Silvia CanepaDepartment of Medical Sciences, University of Turin, Turin, Italy.
Marilena DurazzoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Gabriella GrudenDepartment of Medical Sciences, University of Turin, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD). Although both albuminuria and glomerular filtration rate (GFR) are well-established diagnostic/prognostic biomarkers of DKD, they have important limitations. There is, thus, increasing quest to find novel biomarkers to identify the disease in an early stage and to improve risk stratification. In this review, we will outline the major pitfalls of currently available markers, describe promising novel biomarkers, and discuss their potential clinical relevance. In particular, we will focus on the importance of recent advancements in multi-omic technologies in the discovery of new DKD biomarkers. In addition, we will provide an update on new emerging approaches to explore renal function and structure, using functional tests and imaging.

Indexed as

BiomarkersAlbuminuriaDiabetes Mellitus, Type 2Diabetic NephropathiesDiagnostic Techniques, EndocrineDisease ProgressionGlomerular Filtration RateHumansKidney Failure, ChronicPractice Patterns, Physicians'PrognosisBiomarkersAlbuminuriaBiomarkersDiabetic kidney diseaseGlomerular filtration rateOmics

Identifiers

PMID33528734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.